By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein biomarker and assay development firm NextGen Group announced on Friday that 2010 revenues increased 4 percent to a little more $1.2 million.

That compares to 2009 revenues of slightly less than $1.2 million.

For the year, the UK-based firm's net loss improved 8 percent to $3.3 million, or $.06 per share, from $3.6 million, $.11 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.